The impact of telepharmacy on hypertension management in the United Arab Emirates

Main Article Content


Telepharmacy, Hypertension, Community pharmacies


Objectives: To assess the effectiveness of telepharmacy services delivered by community pharmacies in hypertension management and examine its influence on pharmacists’ ability to identify drug-related problems (DRPs). Methods: This was a 2-arm, randomised, clinical trial conducted among 16 community pharmacies and 239 patients with uncontrolled HTN in the U.A.E over a period of 12 months. The first arm (n=119) received telepharmacy services and the second arm (n=120) received traditional pharmaceutical services. Both arms were followed up to 12 months. Pharmacists self-reported the study outcomes, which primarily were the changes in SBP and DBP from baseline to 12-month meeting. Blood pressure readings were taken at baseline, 3, 6, 9, and 12 months. Other outcomes were the mean knowledge, medication adherence and DRP incidence and types. The frequency and nature of pharmacist interventions in both groups were also reported. Results: The mean SBP and DBP differences were statistically significant across the study groups at 3-, 6-, and 9-month follow-up and 3-, 6-, 9-, 12- month follow-up, respectively. In detail, the mean SBP was reduced from 145.9 mm Hg in the intervention group (IG) and 146.7 mm Hg in the control group (CG) to 124.5, 123.2, 123.5, and 124.9 mm Hg at 3-, 6-, 9-, and 12-month follow-up in the IG and 135.9, 133.8, 133.7, and 132.4 mm Hg at 3-, 6-, 9-, and 12-month follow-up in the CG. The mean DBP was reduced from 84.3 mm Hg in IG and 85.1 mm Hg in CG to 77.6, 76.2, 76.1, and 77.8 mm Hg at 3-, 6-, 9-, and 12-month follow-up in the IG and 82.3, 81.5, 81.5, and 81.9 mm Hg at 3-, 6-, 9-, and 12-month follow-up in the CG. Medication adherence and knowledge of participants in the IG towards hypertension were significantly improved. The DRP incidence and DRPs per patient identified by pharmacists in the intervention and control groups were 2.1% versus 1.0% (p=0.002) and 0.6 versus 0.3 (p=0.001), respectively. The total numbers of pharmacist interventions in the IG and CG were 331 and 196, respectively. The proportions of pharmacist interventions related to patient education, cessation of drug therapy, adjustment of drug dose, and addition of drug therapy across the IG and CG were 27.5% versus 20.9%, 15.4% versus 18.9%, 14.5% versus 14.8%, and 13.9% versus 9.7%, respectively (all with p<0.05). Conclusion: Telepharmacy may have a sustained effect for up to 12 months on blood pressure of patients with hypertension. This intervention also improves pharmacists’ ability to identify and prevent drug-related problems in community setting.

Abstract 634 | PDF Downloads 658


1. World Health Organization. Hypetension. Published 2021. Accessed August 4, 2022. than half of adults,cause of premature death worldwide.
2. Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2013 state and national summary tables. Published 2013. Accessed August 4, 2022.
3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics- 2014;2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
5. Wang TJ, Vasan RS. Epidemiology of Uncontrolled Hypertension in the United States. Circulation. 2005;112(11):1651-1662.
6. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380(9841):611-619.
7. Kusumawardani LA, Andrajati R, Nusaibah A. Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia. J Res Pharm Pract. 2020;9(3):140-145.
8. Abu Farha R, Basheti I, Abu Al Ruz H, et al. Assessment of drug-related problems and their impact on blood pressure control in patients with hypertension. Eur J Hosp Pharm Sci Pract. 2016;23(3):126-130.
9. Margolis KL, Asche SE, Dehmer SP, et al. Long-term Outcomes of the Effects of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Among Adults With Uncontrolled Hypertension: Follow-up of a Cluster Randomized
Clinical Trial. JAMA Netw Open. 2018;1(5):e181617-e181617. 10. Blenkinsopp A, Phelan M, Bourne J, et al. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. Int J Pharm Pract. 2000;8(3):165-175.
11. Zillich AJ, Sutherland JM, Kumbera PA, et al. Hypertension outcomes through blood pressure monitoring and evaluation by 
pharmacists (HOME study). J Gen Intern Med. 2005;20(12):1091-1096.
12. Liu Q, Zhu X, Shen M, et al. Community Pharmacist Services for Hypertensive Patients: A Novel Practice in Shanghai, China. Inq 
J Heal Care Organ Provision, Financ. 2021;58:00469580211020874.
13. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46-56.
14. Unni EJ, Patel K, Beazer IR, et al. Telepharmacy during COVID-19: A Scoping Review. Pharm (Basel, Switzerland). 2021;9(4):183.
15. Fuentes MNV, Shah P, Hale GM. Improving medication adherence in patients with hypertension through pharmacist-led telehealth services. J Telemed Telecare. 2022;28(8):613-617. 
16. Raoul Bell, Nils Brandenburg, Axel Buchner JH, et al. G*Power: Statistical Power Analyses for Windows and Mac. Published 2007.Accessed June 30, 2020.
17. AbuRuz SM, Bulatova NR, Yousef AM. Validation of a comprehensive classification tool for treatment-related problems. Pharm World Sci. 2006;28:222-232.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
19. de Oliveira-Filho AD, Morisky DE, Neves SJF, et al. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm. 2014;10(3):554-561.
20. Basile JN. Systolic blood pressure. BMJ. 2002;325(7370):917-918.
21. Margolis KL, Kerby TJ, Asche SE, et al. Design and rationale for Home Blood Pressure Telemonitoring and Case Management
to Control Hypertension (HyperLink): a cluster randomized trial. Contemp Clin Trials. 2012;33(4):794-803.
22. Asche SE, O’Connor PJ, Dehmer SP, et al. Patient characteristics associated with greater blood pressure control in a randomized trial of home blood pressure telemonitoring and pharmacist management. J Am Soc Hypertens. 2016;10(11):873-880.
23. Guadamuz JS, McCormick CD, Choi S, et al. Telepharmacy and medication adherence in urban areas. J Am Pharm Assoc (2003).
24. Hedegaard U, Kjeldsen LJ, Pottegård A, et al. Improving Medication Adherence in Patients with Hypertension: A Randomized Trial. Am J Med. 2015;128(12):1351-1361.
25. Pinsonneault A, Addas S, Qian C, et al. Integrated Health Information Technology and the Quality of Patient Care: A Natural Experiment. J Manag Inf Syst. 2017;34(2):457-486.
26. Hefti E, Wei B, Engelen K. Access to Telepharmacy Services May Reduce Hospital Admissions in Outpatient Populations During the COVID-19 Pandemic. Telemed J e-health Off J Am Telemed Assoc. 2022;28(9):1324-1331. tmj.2021.0420
27. AbuRuz S, Jaber D, Basheti I, et al. Impact of pharmacist interventions on drug-related problems in general surgery patients: a randomised controlled trial. Eur J Hosp Pharm Sci Pract. 2021;28(Suppl 2):e72-e78.
28. Jazbar J, Locatelli I, Horvat N, et al. Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study. Res Soc Adm Pharm. 2018;14(6):572-580.
29. Wuyts J, Maesschalck J, De Wulf I, et al. Studying the impact of a medication use evaluation by the community pharmacist (Simenon): Drug-related problems and associated variables. Res Soc Adm Pharm. 2020;16:1100-1110. https://doi. org/10.1016/j.sapharm.2019.11.008
30. Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. Int J Behav Healthc Res. 2011;2:320-332.

Most read articles by the same author(s)